-
公开(公告)号：US20120190817A2
公开(公告)日：2012-07-26
申请号：US13181460
申请日：2011-07-12
申请人： Jason Hanko , David Engers , Eric Hagen , Valeriya Smolenskaya , Jeffrey Stults
发明人： Jason Hanko , David Engers , Eric Hagen , Valeriya Smolenskaya , Jeffrey Stults
IPC分类号： C07K11/02
摘要： The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.
摘要翻译： 本公开内容提供式I化合物的固体形式。在一些实施方案中，本公开内容提供化合物I的结晶形式。在一些实施方案中，本公开内容提供化合物I的溶剂合物形式。在一些实施方案中，本公开内容提供无定形 化合物I.
-
公开(公告)号：US20120029008A1
公开(公告)日：2012-02-02
申请号：US13187749
申请日：2011-07-21
申请人： Jason Hanko , Petinka Vlahova
发明人： Jason Hanko , Petinka Vlahova
IPC分类号： A61K31/485 , A61P29/00 , C07D489/00
CPC分类号： A61K31/485
摘要： The present invention is directed to novel crystalline and amorphous forms of nalbuphine hydrochloride.
摘要翻译： 本发明涉及盐酸奈哌芬的新型结晶和无定形形式。
-
公开(公告)号：US20110275695A1
公开(公告)日：2011-11-10
申请号：US12997499
申请日：2009-06-11
CPC分类号： C07D337/14
摘要： The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms of zotepine hydrochloride to treat central nervous system disorders and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及盐酸妥洛司定的结晶形式，包括zotepine的盐酸盐结晶盐酸盐和盐酸妥替托盐酸盐与苯甲酸两种共晶体。 描述了盐酸替罗定的这些晶型的制备和表征。 本发明还涉及盐酸替罗他宾的结晶形式治疗中枢神经系统疾病和含有它们的药物组合物的治疗用途。
-
4.发明申请公开(公告)号：US20070244185A1
公开(公告)日：2007-10-18
申请号：US11709299
申请日：2007-02-21
申请人： Jason Hanko
发明人： Jason Hanko
IPC分类号： A61K31/381 , A61P11/06 , C07D333/50
CPC分类号： C07D333/58 , A61K31/381 , C07D333/50
摘要： Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.
摘要翻译： 公开了可用于药物应用的（+） - R-Zileuton的结晶形式。 （+） - R-Zileuton的特殊单晶形式的特征在于各种性质和物理测量。 此外，还讨论了生产结晶（+） - R-Zileuton，并用于抑制受试者中的5-脂氧合酶活性以治疗许多疾病的方法。
-
公开(公告)号：US08536191B2
公开(公告)日：2013-09-17
申请号：US13187749
申请日：2011-07-21
申请人： Jason Hanko , Petinka Vlahova
发明人： Jason Hanko , Petinka Vlahova
IPC分类号： A61K31/485 , C07D489/02
CPC分类号： A61K31/485
摘要： The present invention is directed to novel crystalline and amorphous forms of nalbuphine hydrochloride.
摘要翻译： 本发明涉及盐酸奈哌芬的新型结晶和无定形形式。
-
公开(公告)号：US20120046442A1
公开(公告)日：2012-02-23
申请号：US13181460
申请日：2011-07-12
IPC分类号： C07K11/02
摘要： The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.013 秒)
